BARD1 and breast carcinoma: Tamoxifen-resistant breast cancer cells highly overexpress BARD1 and BRCA1, resulting in chemoresistance to DNA-damaging therapies including cisplatin and doxorubicin, but not to paclitaxel (Zhu et al., 2018).